Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 28Xls
2D Structure
Also known as: 7758-87-4, Tricalcium phosphate, Synthos, Calcium phosphate tribasic, Calcium orthophosphate, Tricalcium diphosphate
Molecular Formula
Ca3O8P2
Molecular Weight
310.18  g/mol
InChI Key
QORWJWZARLRLPR-UHFFFAOYSA-H
FDA UNII
K4C08XP666

Calcium Phosphate is the calcium salt of phosphoric acid with widely used applications. This agent can be used as a countermeasure for exposure to strontium and radium radionuclides. Upon oral uptake, calcium phosphate competes for and blocks the absorption of radium (Ra-226) and strontium (Sr-90) in the gastrointestinal (GI) tract.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
tricalcium;diphosphate
2.1.2 InChI
InChI=1S/3Ca.2H3O4P/c;;;2*1-5(2,3)4/h;;;2*(H3,1,2,3,4)/q3*+2;;/p-6
2.1.3 InChI Key
QORWJWZARLRLPR-UHFFFAOYSA-H
2.1.4 Canonical SMILES
[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[Ca+2].[Ca+2].[Ca+2]
2.2 Other Identifiers
2.2.1 UNII
K4C08XP666
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. 7758-87-4

2. Tricalcium Phosphate

3. Synthos

4. Calcium Phosphate Tribasic

5. Calcium Orthophosphate

6. Tricalcium Diphosphate

7. Calcigenol Simple

8. Beta-tcp

9. Tricalcium Orthophosphate

10. Beta-tricalcium Phosphate

11. Calcium Tertiary Phosphate

12. Tertiary Calcium Phosphate

13. Phosphoric Acid, Calcium Salt (2:3)

14. Fema No. 3081

15. Calcium Phosphate (3:2)

16. Tri-calcium Phosphate

17. Tricalcium;diphosphate

18. 10103-46-5

19. Calciresorb;tcp

20. Phosphoric Acid, Calcium Salt

21. Tricalcium Bis(phosphate)

22. Alpha-tricalcium Phosphate

23. Ins No.341(iii)

24. Chebi:9679

25. Ins-341(iii)

26. E-341(iii)

27. K4c08xp666

28. Synthograft

29. Bonarka

30. Cerasorb

31. Osferion

32. Natural Whitlockite

33. Caswell No. 148

34. Ceredex

35. Multifos

36. Ostram

37. Vitoss

38. Calciumphosphate

39. Tricos

40. Calipharm T

41. Tricafos P

42. 21063-37-6

43. Tricalcium Bis(orthophosphate)

44. Ccris 3668

45. Hsdb 879

46. Jax Tcp

47. Calcium Phosphate (ca3(po4)2)

48. Calcium Orthophosphate, Tri-(tert)

49. Tricalcium Phosphate (ca3(po4)2)

50. Einecs 231-840-8

51. Einecs 233-283-6

52. Unii-97z1wi3ndx

53. Epa Pesticide Chemical Code 076401

54. Posture (calcium Supplement)

55. Bone Phosphate

56. Phosphoric Acid Calcium(2+) Salt (2:3)

57. Unii-k4c08xp666

58. Ca3(po4)2

59. Calcium-phosphate

60. Alpha-tcp

61. Calcium Phosphates

62. Tricalciumphosphate

63. Posture (tn)

64. Hydroxyapatite Powder

65. Mfcd00015984

66. Calcigenol

67. Calcium Phosphate Basic

68. Beta Tricalcium Phosphate

69. Ai3-25607

70. Ec 231-840-8

71. 97z1wi3ndx

72. Chembl2106566

73. Dtxsid1049803

74. Calcium Phosphate [who-dd]

75. Tricalcium Phosphate [fhfi]

76. Tricalcium Phosphate [inci]

77. Precipitated Calcium Phosphate

78. Akos015833108

79. Phosphoric Acid, Calcium Salt (1:?)

80. Cx-0072

81. Db11348

82. Calcium Phosphate, Tribasic [mi]

83. Tricalcium Bis(orthophosphate), With A Fluorine Content Of Less Than 0,005 % By Weight On The Dry Anhydrous Product

84. Calcium Phosphate, Tribasic (ca.37% Ca)

85. Calcium Phosphate, Tribasic [hsdb]

86. Calcium Phosphate,anhydrous [vandf]

87. C3736

88. Cs-0013475

89. Ft-0645103

90. C08136

91. D00938

92. Q278387

93. Calcium Phosphate, Reagent For Transient & Stable Dna Transfections

94. Beta-tri-calcium Phosphate, >=95% Beta-phase Basis (unsintered Powder)

95. Calcium Phosphate, Purum P.a., >=96.0% (calc. As Ca3(po4)2, Kt)

96. Tricalcium Phosphate Hydrate, Nanopowder, <200 Nm Particle Size (bet)

97. Alpha-tri-calcium Phosphate, Puriss. P.a., >=75% Alpha-phase Basis (sinterted Powder)

98. Alpha-tri-calcium Phosphate, Reagent For Transient & Stable Dna Transfections

99. Beta-tri-calcium Phosphate, Puriss. P.a., >=95% Beta-phase Basis (sintered Powder)

100. Beta-tri-calcium Phosphate, Puriss. P.a., >=98% Beta-phase Basis (sintered Powder)

101. Beta-tri-calcium Phosphate, Puriss. P.a., >=98% Beta-phase Basis (unsintered Powder)

102. Calcium Phosphate (3:2) Mixture With Calcium Phosphate (1:1) [who-ip]

2.4 Create Date
2005-06-24
3 Chemical and Physical Properties
Molecular Weight 310.18 g/mol
Molecular Formula Ca3O8P2
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count8
Rotatable Bond Count0
Exact Mass309.7946135 g/mol
Monoisotopic Mass309.7946135 g/mol
Topological Polar Surface Area173 Ų
Heavy Atom Count13
Formal Charge0
Complexity36.8
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count5
4 Drug and Medication Information
4.1 Therapeutic Uses

... CHIEFLY USED AS GASTRIC ANTACID ... VALUABLE SOURCE OF CALCIUM ION, ESPECIALLY WHEN IT IS DESIRED TO SUPPLY BOTH CALCIUM & PHOSPHORUS. /FORMER USE/

Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1528


... /THIS/ ORALLY ADMIN CALCIUM ... /SALT/ CAN BE USED IN TREATMENT OF MILD & LATENT HYPOCALCEMIC TETANY & FOR MAINTENANCE THERAPY ... .

American Medical Association, Council on Drugs. AMA Drug Evaluations. 2nd ed. Acton, Mass.: Publishing Sciences Group, Inc., 1973., p. 202


AN EXCELLENT SOURCE OF BOTH CALCIUM AND PHOSPHORUS USEFUL IN SUPPLEMENTING CALCIUM INTAKE, AS, FOR EXAMPLE, DURING PREGNANCY & LACTATION, OR AS SOURCE OF CALCIUM IN DISEASES OF CALCIUM DEFICIENCY.

Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 770


Calcium replenisher

Budavari, S. (ed.). The Merck Index - Encyclopedia of Chemicals, Drugs and Biologicals. Rahway, NJ: Merck and Co., Inc., 1989., p. 256


For more Therapeutic Uses (Complete) data for TRICALCIUM PHOSPHATE (6 total), please visit the HSDB record page.


4.2 Drug Warning

... CONTRAINDICATED IN TREATMENT OF HYPOCALCEMIA WITH HYPERPHOSPHATEMIA, WHICH MAY OCCUR IN HYPOPARATHYROIDISM AND RENAL FAILURE.

American Medical Association, Council on Drugs. AMA Drug Evaluations. 2nd ed. Acton, Mass.: Publishing Sciences Group, Inc., 1973., p. 201


Ceramic implant materials, including tricalcium phosphate, are biocompatible and are currently being used to restore alveolar bone loss resulting from periodontal disease, endodontic infections, and residual alveolar ridge resorption. However, use of such a material in this case led to persistent infection and additional bone destruction. Thus, the use of a ceramic implant material to accelerate periapical bone repair is not recommended in areas where a chronic bacterial infection is present.

PMID:3457349 Barkhordar RA, Meyer JR; Oral Surg Oral Med Oral Pathol 61 (2): 201-6 (1986)


4.3 Drug Indication

For use as an over the counter calcium and phosphate supplement, antacid, or a source of calcium and phosphate in toothpaste.


FDA Label


5 Pharmacology and Biochemistry
5.1 Pharmacology

Calcium phosphate reacts with acid in the stomach to raise the pH. In toothpaste it provides a source of calcium and phosphate ions to support remineralization of the teeth. As a supplement it provides a source of calcium and phospate, both of which are important ions in bone homeostasis.


5.2 FDA Pharmacological Classification
5.2.1 Pharmacological Classes
Calcium [CS]; Cations, Divalent [CS]; Increased Coagulation Factor Activity [PE]; Blood Coagulation Factor [EPC]
5.3 ATC Code

A - Alimentary tract and metabolism

A12 - Mineral supplements

A12A - Calcium

A12AA - Calcium

A12AA01 - Calcium phosphate


5.4 Absorption, Distribution and Excretion

/Ortho/ phosphate is absorbed from, and to a limited extent secreted into, the gastrointestinal tract. Transport of phosphate from the gut lumen is an active, energy-dependent process that is modified by several factors. ... Vitamin D stimulates phosphate absorption, an effect reported to precede its action on calcium ion transport. In adults, about two thirds of the ingested phosphate is absorbed, and that which is absorbed is almost entirely excreted into the urine. In growing children, phosphate balance is positive. Concentrations of phosphate in plasma are higher in children than in adults. This "hyperphosphatemia" decreases the affinity of hemoglobin for oxygen and is hypothesized to explain the physiological "anemia" of childhood. /Phosphates/

Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1524


5.5 Metabolism/Metabolites

A defect in phosphate metabolism occurs in a variety of diseases. ... Rickets ... Osteomalacia ... Primary or Secondary Hyperparathyroidism ... Chronic Renal Failure. /Phosphates/

Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1525


5.6 Mechanism of Action

The phosphate ions in calcium phosphate likely react with hydrochloric acid in the stomach to neutralize the pH. In toothpaste and in systemic circulation, calcium phosphate provides a source of calcium and phosphate ions to support remineralization of the teeth and bone homeostasis respectively. The increase in plasma calcium reduces calcium flux from osteocyte activity by reducing the secretion of parathyroid hormone (PTH). Calcium does this by stimulating a G-protein coupled calcium receptor on the surface of parathyroid cells. The reduction in calcium flux increases the amount of calcium deposited in bone resulting in an increase in bone mineral density. The reduction in PTH secretion also reduces the amount of vitamin D metabolized to its active form, calcidiol. Since calcidiol increases the expression of calcium dependent ATPases and transient receptor potential cation channel subfamily V member 6 (TRPV6) both of which are involved in calcium uptake from the gut, a reduction in calcidiol results in less calcium absorption. Additionally, TRPV5, the channel responsible for calcium reabsorption in the kidney, is downregulated when PTH secretion is reduced thus increasing calcium excretion via the kidneys. Another hormone, calitonin, is likely involved in the reduction of bone resorption during periods of high plasma calcium.